Enesi Pharma's ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe |
| September 29, 2020 | September 2020 Bond Updates |
|
OXFORD, England, Sept. 29, 2020 /PRNewswire/ -- Enesi Pharma ("Enesi"), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive... |
| View more at: https://www.prnewswire.com:443/news-releases/enesi-pharmas-implavax-enabled-solid-dose-modified-live-virus-vaccine-produces-neutralising-antibody-and-t-cell-responses-equivalent-to-liquid-vaccine-delivered-via-needle-and-syringe-301138951.html |
| Related News |